Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease
| Autor: | Karin Dannaeus, Harriet Rönnholm, Theo Palmer, Ming Zhao, Olof Zachrisson, Anders Haegerstrand, Ann Marie Janson Lang, Cesare Patrone, Lilian Wikstrom, Elisabet Nielsen, Annica Andersson, Michael P. Hill, Kristofer Delfani, Johan Haggblad, Ruben Isacson, Alison L. McCormack, Donato A. Di Monte |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Parkinson's disease Time Factors Neurotoxins Becaplermin Subventricular zone Motor Activity Drug Administration Schedule Rats Sprague-Dawley Cellular and Molecular Neuroscience chemistry.chemical_compound Mice Neurotrophic factors Internal medicine medicine Animals Oxidopamine Cell Proliferation Tyrosine hydroxylase Cell growth business.industry Dopaminergic Cytarabine Parkinson Disease Proto-Oncogene Proteins c-sis medicine.disease Neural stem cell Rats Mice Inbred C57BL Disease Models Animal Endocrinology medicine.anatomical_structure chemistry 1-Methyl-4-phenyl-1 2 3 6-tetrahydropyridine Angiogenesis Inducing Agents Neurology (clinical) business Immunosuppressive Agents |
| Zdroj: | Journal of Parkinson's disease. 1(1) |
| ISSN: | 1877-718X |
| Popis: | Parkinson's disease is characterized by motor deficits caused by loss of midbrain dopaminergic neurons. Neurotrophic factors and cell transplantation have partially restored function in models of Parkinson's disease, but have had limited effects in humans. Here we show that intracerebroventricular administration of platelet-derived growth factor-BB can offer an alternative strategy to restore function in Parkinson's disease; In animal models of nigrostriatal injury, a two weeks treatment with platelet-derived growth factor-BB resulted in long-lasting restoration of striatal dopamine transporter binding sites and expression of nigral tyrosine hydroxylase. It also normalized amphetamine-induced rotational behavior in 6-hydroxydopamine lesioned rats. Platelet-derived growth factor-BB promoted proliferation of neural progenitor cells in the subventricular zone. The effects on dopaminergic neurons and functional recovery could be blocked by co-infusion with a proliferation inhibitor, indicating a link between the proliferative and anti-parkinsonian effects. Based on the current data, we consider platelet-derived growth factor-BB a clinical candidate drug for treatment of Parkinson's disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|